Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Calroy Health Sciences
Age
25–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Mild hypertension defined as brachial artery blood pressure greater than or equal to 130 mm Hg systolic and less than or equal to 140 mm Hg systolic or greater than or equal to 85 mm Hg diastolic or less than 90 mm Hg diastolic while taking or not taking antihypertensive drugs.
Not currently taking nitric oxide supplements, and not consuming nitric oxide supplements for 14 days prior to screening.
Ability to give written informed consent.
Ability to adhere to study protocol directives and procedures.
You may not be if
Initiated or had a dose change of an antihypertensive agent less than 6 months prior to the enrollment date.
A positive nitric oxide saliva test strip (result \>2) on the day of Screening.
A positive nitric oxide saliva test strip (result \>2) on the day of Baseline/Visit 1.
A high saliva NO3 test strip result (result \>2) but a low NO test strip result.
Current use of antibiotics.
Chronic steroid use \>15 mg daily.
Previous myocardial infarction less than 2 years of enrollment date.
Unstable angina.
Previous stroke or transient ischemic attack (TIA) less than 2 years of enrollment date.
Uncompensated congestive heart failure (CHF).
Previous percutaneous transluminal coronary angioplasty (PTCA) or stent less than 2 years of enrollment date.
Previous coronary arterial bypass graft (CABG) less than 2 years of enrollment date.
Known or previous cancer less than 5 years of enrollment date.
Type 1 diabetes mellitus.
Prescribed dosing with insulin, injectable or inhaled.
Pregnant females.
Females of child bearing age not on an accepted contraception control method.
Allergy/sensitivity to study products or their ingredients.
Current drug or alcohol use or dependence that, in the opinion of the principal investigator, would interfere with adherence to study requirements.
Inability or unwillingness of individual to give written informed consent.
Current or past participation within 30 calendar days in another clinical trial, as warranted by the administration of this intervention.
